The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

• Tipo: Artigo em Revista Científica Internacional
• Data: 2021

Autores

Bousquet, J (Autor) Outra; Jutel, M (Autor) Outra; Pfaar, O (Autor) Outra; Fonseca, J (Autor) FMUP; Agache, I (Autor) Outra; Czarlewski, W (Autor) Outra; Bachert, C (Autor) Outra; Bergmann, KC (Autor) Outra; Cruz, AA (Autor) Outra; Klimek, L (Autor) Outra; Kvedariene, V (Autor) Outra; Larenas Linnemann, DE (Autor) Outra; Papadopoulos, NG (Autor) Outra; Patella, V (Autor) Outra; Regateiro, FS (Autor) Outra; Scichilone, N (Autor) Outra; Shamji, MH (Autor) Outra; Sheikh, A (Autor) Outra; Valovirta, E (Autor) Outra; Ventura, MT (Autor) Outra; Zuberbier, T (Autor) Outra

Revista

Título: Journal of Allergy and Clinical Immunology: In Practice

Vol. 9

Páginas: 1805-1812

ISSN: 2213-2198

Editora: Elsevier

Indexação

ISI Web of Knowledge - 16 Citações

Scopus - 14 Citações

Outras Informações

ID Authenticus: P-00T-WDX

DOI: 10.1016/j.jaip.2021.02.035

Abstract (EN): Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis and/or asthma. Many international or national practice guidelines have been produced, but the evidence-based method varies and they do not usually propose care pathways. The present article considers the possible role of mobile health in AIT for allergic rhinitis/asthma. There are no currently available validated biologic biomarkers that can predict AIT success, and mobile health biomarkers have some relevance. In the current article, the following aspects will be discussed: patient stratification for AIT, symptom-medication scores for the follow-up of patients, clinical trials, as well as the approach of the European Academy of Allergy and Clinical Immunology. (C) 2021 American Academy of Allergy, Asthma & Immunology

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 8